Neuroimaging in moderate MDMA use: A systematic review

Neuroscience and Biobehavioral Reviews

Volumn 62, Issue , 2016, Pages 21-34

  Mueller, F ^a   Lenz, C ^a   Steiner, M ^a   Dolder, P C ^b   Walter, M ^a   Lang, U E ^a   Liechti, M E ^b   Borgwardt, S ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

3,4 Methylenedioxymethamphetamine; Adverse effects; Chronic effects; Ecstasy; MDMA; Moderate use; MRI; Neuroimaging; Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN 2A RECEPTOR; MIDOMAFETAMINE; PSYCHEDELIC AGENT; STREET DRUG;

ALCOHOL CONSUMPTION; ANGULAR GYRUS; ASSOCIATIVE MEMORY; BOLD SIGNAL; CANNABIS USE; DATA ANALYSIS; DATA EXTRACTION; DORSOLATERAL PREFRONTAL CORTEX; DRUG USE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGING; INFERIOR FRONTAL GYRUS; INFERIOR PARIETAL CORTEX; INFERIOR PARIETAL GYRUS; INFERIOR TEMPORAL REGION; LIFETIME ECSTASY USE; MODERATE ECSTACY USE; NEUROANATOMY; NEUROCHEMICAL IMAGING; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL GYRUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUBLICATION; PUTAMEN; QUALITY CONTROL; REVIEW; SAMPLE SIZE; SEMANTIC MEMORY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; STANDARDIZATION; STRUCTURAL MAGNETIC RESONANCE IMAGING; SUPERIOR TEMPORAL GYRUS; SYSTEMATIC REVIEW; TASK PERFORMANCE; WORKING MEMORY; AMPHETAMINE-RELATED DISORDERS; ANIMAL; BRAIN; DRUG EFFECTS;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; BRAIN; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROIMAGING; STREET DRUGS;

EID: 84953854211     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.12.010     Document Type: Review

References (59)

1. Bauernfeind A.L., Dietrich M.S., Blackford J.U., Charboneau E.J., Lillevig J.G., Cannistraci C.J., Woodward N.D., Cao A., Watkins T., Di Iorio C.R., Cascio C., Salomon R.M., Cowan R.L. Human Ecstasy use is associated with increased cortical excitability: an fMRI study. Neuropsychopharmacology 2011, 36:1127-1141.
2. Becker B., Wagner D., Koester P., Bender K., Kabbasch C., Gouzoulis-Mayfrank E., Daumann J. Memory-related hippocampal functioning in ecstasy and amphetamine users: a prospective fMRI study. Psychopharmacology (Berl.) 2013, 225:923-934.
3. Becker B., Wagner D., Koester P., Tittgemeyer M., Mercer-Chalmers-Bender K., Hurlemann R., Zhang J., Gouzoulis-Mayfrank E., Kendrick K.M., Daumann J. Smaller amygdala and medial prefrontal cortex predict escalating stimulant use. Brain 2015, 138:2074-2086.
4. Bossong M.G., Jager G., Bhattacharyya S., Allen P. Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies. Curr. Pharm. Des. 2014, 20:2114-2125.
5. Brunt T.M., Koeter M.W., Niesink R.J., van den Brink W. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology (Berl.) 2012, 220:751-762.
6. Capela J.P., Carmo H., Remião F., Bastos M.L., Meisel A., Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol. 2009, 39:210-271.
7. Carvalho M., Carmo H., Costa V.M., Capela J.P., Pontes H., Remião F., Carvalho F., Bastos M.e.L. Toxicity of amphetamines: an update. Arch. Toxicol. 2012, 86:1167-1231.
8. Cole J.C., Bailey M., Sumnall H.R., Wagstaff G.F., King L.A. The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 2002, 97:1531-1536.
9. Cowan R.L., Lyoo I.K., Sung S.M., Ahn K.H., Kim M.J., Hwang J., Haga E., Vimal R.L., Lukas S.E., Renshaw P.F. Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. Drug Alcohol Depend. 2003, 72:225-235.
10. Cowan R.L., Haga E., deB Frederick B., Dietrich M.S., Vimal R.L., Lukas S.E., Renshaw P.F. MDMA use is associated with increased spatial BOLD fMRI visual cortex activation in human MDMA users. Pharmacol. Biochem. Behav. 2006, 84:219-228.
11. Cowan R.L., Bolo N.R., Dietrich M., Haga E., Lukas S.E., Renshaw P.F. Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users. Psychiatry Res. 2007, 155:179-188.
12. de Win M.M., Reneman L., Reitsma J.B., den Heeten G.J., Booij J., van den Brink W. Mood disorders and serotonin transporter density in ecstasy users - the influence of long-term abstention, dose, and gender. Psychopharmacology 2004, 173:376-382.
13. Daumann J., Fimm B., Willmes K., Thron A., Gouzoulis-Mayfrank E. Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study. Brain Res. Cogn. Brain Res. 2003, 16:479-487.
14. Daumann J., Koester P., Becker B., Wagner D., Imperati D., Gouzoulis-Mayfrank E., Tittgemeyer M. Medial prefrontal gray matter volume reductions in users of amphetamine-type stimulants revealed by combined tract-based spatial statistics and voxel-based morphometry. Neuroimage 2011, 54:794-801.
15. Daumann J., Schnitker R., Weidemann J., Schnell K., Thron A., Gouzoulis-Mayfrank E. Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users. NeuroReport 2003, 14:1983-1987.
16. de Win M.M., Jager G., Booij J., Reneman L., Schilt T., Lavini C., Olabarriaga S.D., den Heeten G.J., van den Brink W. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 2008, 131:2936-2945.
17. De Win M.M., Jager G., Vervaeke H.K., Schilt T., Reneman L., Booij J., Verhulst F.C., Den Heeten G.J., Ramsey N.F., Korf D.J., Van den Brink W. The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. Int. J. Methods Psychiatr. Res. 2005, 14:167-185.
18. de Win M.M., Reneman L., Jager G., Vlieger E.J., Olabarriaga S.D., Lavini C., Bisschops I., Majoie C.B., Booij J., den Heeten G.J., van den Brink W. A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacology 2007, 32:458-470.
19. Di Iorio C.R., Watkins T.J., Dietrich M.S., Cao A., Blackford J.U., Rogers B., Ansari M.S., Baldwin R.M., Li R., Kessler R.M., Salomon R.M., Benningfield M., Cowan R.L. Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users. Arch. Gen. Psychiatry 2012, 69:399-409.
20. Dumont G.J., Verkes R.J. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J. Psychopharmacol. 2006, 20:176-187.
21. EMCDDA European Drug Report 2015: Trends and Developments 2015, Available from: http://www.thehealthwell.info/node/872085 (accessed 10.09.15).
22. Erritzoe D., Frokjaer V.G., Holst K.K., Christoffersen M., Johansen S.S., Svarer C., Madsen J., Rasmussen P.M., Ramsøy T., Jernigan T.L., Knudsen G.M. In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users. Arch. Gen. Psychiatry 2011, 68:562-576.
23. Fox H.C., Parrott A.C., Turner J.J. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J. Psychopharmacol. 2001, 15:273-281.
24. Freedman R.R., Johanson C.E., Tancer M.E. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl.) 2005, 183:248-256.
25. Giraudon I., Bello P.Y. Monitoring ecstasy content in France: results from the National Surveillance System 1999-2004. Subst. Use Misuse 2007, 42:1567-1578.
26. Jacobsen L.K., Mencl W.E., Pugh K.R., Skudlarski P., Krystal J.H. Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology (Berl.) 2004, 173:383-390.
27. Jager G., de Win M.M., Vervaeke H.K., Schilt T., Kahn R.S., van den Brink W., van Ree J.M., Ramsey N.F. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study. Psychopharmacology (Berl.) 2007, 193:403-414.
28. Karageorgiou J., Dietrich M.S., Charboneau E.J., Woodward N.D., Blackford J.U., Salomon R.M., Cowan R.L. Prior MDMA (Ecstasy) use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: an fMRI study. Neuroimage 2009, 46:817-826.
29. Koester P., Tittgemeyer M., Wagner D., Becker B., Gouzoulis-Mayfrank E., Daumann J. Cortical thinning in amphetamine-type stimulant users. Neuroscience 2012, 221:182-192.
30. Koester P., Volz K.G., Tittgemeyer M., Wagner D., Becker B., Gouzoulis-Mayfrank E., Daumann J. Decision-making in polydrug amphetamine-type stimulant users: an fMRI study. Neuropsychopharmacology 2013, 38:1377-1386.
31. Liechti M.E., Gamma A., Vollenweider F.X. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl.) 2001, 154:161-168.
32. Liechti M.E., Vollenweider F.X. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum. Psychopharmacol. 2001, 16:589-598.
33. Mackey S., Stewart J.L., Connolly C.G., Tapert S.F., Paulus M.P. A voxel-based morphometry study of young occasional users of amphetamine-type stimulants and cocaine. Drug Alcohol Depend. 2014, 135:104-111.
34. Martín-Santos R., Fagundo A.B., Crippa J.A., Atakan Z., Bhattacharyya S., Allen P., Fusar-Poli P., Borgwardt S., Seal M., Busatto G.F., McGuire P. Neuroimaging in cannabis use: a systematic review of the literature. Psychol. Med. 2010, 40:383-398.
35. Mc Fadden K., Gillespie J., Carney B., O'Driscoll D. Development and application of a high-performance liquid chromatography method using monolithic columns for the analysis of ecstasy tablets. J. Chromatogr. A 2006, 1120:54-60.
36. Mechtcheriakov S., Brenneis C., Egger K., Koppelstaetter F., Schocke M., Marksteiner J. A widespread distinct pattern of cerebral atrophy in patients with alcohol addiction revealed by voxel-based morphometry. J. Neurol. Neurosurg. Psychiatry 2007, 78:610-614.
37. Mithoefer M.C., Wagner M.T., Mithoefer A.T., Jerome L., Doblin R. The safety and efficacy of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J. Psychopharmacol. 2011, 25:439-452.
38. Moher D., Shamseer L., Clarke M., Ghersi D., Liberati A., Petticrew M., Shekelle P., Stewart L.A., Group P.-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015, 4:1.
39. Moreno-Lopez L., Stamatakis E.A., Fernandez-Serrano M.J., Gomez-Rio M., Rodriguez-Fernandez A., Perez-Garcia M., Verdejo-Garcia A. Neural correlates of the severity of cocaine, heroin, alcohol, MDMA and cannabis use in polysubstance abusers: a resting-PET brain metabolism study. PLoS ONE 2012, 7:e39830.
40. Morley K.C., Li K.M., Hunt G.E., Mallet P.E., McGregor I.S. Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ("Ecstasy") in rats. Neuropharmacology 2004, 46:954-965.
41. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J. Psychoact. Drugs 1986, 18:305-313.
42. Oehen P., Traber R., Widmer V., Schnyder U. A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J. Psychopharmacol. 2013, 27:40-52.
43. Palhol F., Boyer S., Naulet N., Chabrillat M. Impurity profiling of seized MDMA tablets by capillary gas chromatography. Anal. Bioanal. Chem. 2002, 374:274-281.
44. Pan P., Shi H., Zhong J., Xiao P., Shen Y., Wu L., Song Y., He G. Chronic smoking and brain gray matter changes: evidence from meta-analysis of voxel-based morphometry studies. Neurol. Sci. 2013, 34:813-817.
45. Parrott A.C. Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research. Hum. Psychopharmacol. 2013, 28:289-307.
46. Parrott A.C. The potential dangers of using MDMA for psychotherapy. J. Psychoact. Drugs 2014, 46:37-43.
47. Reneman L., Booij J., de Bruin K., Reitsma J.B., de Wolff F.A., Gunning W.B., den Heeten G.J., van den Brink W. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001, 358:1864-1869.
48. Roberts G.M., Nestor L., Garavan H. Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task. Brain Res. 2009, 1292:71-81.
49. Salomon R.M., Karageorgiou J., Dietrich M.S., McLellan J.Y., Charboneau E.J., Blackford J.U., Cowan R.L. MDMA (Ecstasy) association with impaired fMRI BOLD thalamic coherence and functional connectivity. Drug Alcohol Depend. 2012, 120:41-47.
50. Schmid Y., Hysek C.M., Simmler L.D., Crockett M.J., Quednow B.B., Liechti M.E. Differential effects of MDMA and methylphenidate on social cognition. J. Psychopharmacol. 2014, 28:847-856.
51. Schmid Y., Enzler F., Gasser P., Grouzmann E., Preller K.H., Vollenweider F.X., Brenneisen R., Müller F., Borgwardt S., Liechti M.E. Acute effects of lysergic acid diethylamide in healthy subjects. Biol. Psychiatry 2015, 78(October (8)):544-553. 10.1016/j.biopsych.2014.11.015.
52. Touriño C., Zimmer A., Valverde O. THC prevents MDMA neurotoxicity in mice. PLoS ONE 2010, 5:e9143.
53. UNODC World Drug Report 2014 2014, Available from: http://www.unodc.org/wdr2014/ (accessed 11.11.15).
54. Vogels N., Brunt T.M., Rigter S., van Dijk P., Vervaeke H., Niesink R.J. Content of ecstasy in the Netherlands: 1993-2008. Addiction 2009, 104:2057-2066.
55. von Sydow K., Lieb R., Pfister H., Höfler M., Wittchen H.U. Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults-a transient phenomenon? Results from a longitudinal community study. Drug Alcohol Depend. 2002, 66:147-159.
56. Watkins T.J., Raj V., Lee J., Dietrich M.S., Cao A., Blackford J.U., Salomon R.M., Park S., Benningfield M.M., Di Iorio C.R., Cowan R.L. Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processing. Psychopharmacology (Berl) 2013, 227:41-54.
57. Webb E., Ashton C.H., Kelly P., Kamali F. Alcohol and drug use in UK university students. Lancet 1996, 348:922-925.
58. Wood D.M., Stribley V., Dargan P.I., Davies S., Holt D.W., Ramsey J. Variability in the 3,4-methylenedioxymethamphetamine content of `ecstasy' tablets in the UK. Emergency Med. J. 2011, 28:764-765.
59. Wu L.T., Parrott A.C., Ringwalt C.L., Yang C., Blazer D.G. The variety of ecstasy/MDMA users: results from the National Epidemiologic Survey on alcohol and related conditions. Am. J. Addict. 2009, 18:452-461.